Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Drug attack aims to stop mantle cell lymphoma without chemo

NCT ID NCT06522386

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—as a first treatment for people with mantle cell lymphoma who have not had any prior therapy. The goal is to see how many patients achieve a complete response (no cancer detected) after the combination therapy, while also monitoring side effects. The study enrolls 50 adults aged 18 and older with confirmed CD20-positive MCL.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pirtobrutinib, rituximab, and venetoclax
What this could lead to
If successful, this combination could offer a highly effective, chemotherapy-free first treatment for mantle cell lymphoma, potentially leading to long-term disease control.
What could go wrong
This is an early-phase (Phase 2) study with only 50 participants, so results may not apply to all patients. Side effects from the drug combination could be significant, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.